Talaris Therapeutics IPO

Talaris Therapeutics is a late-clinical stage biotechnology company developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe auto-immune and immune-mediated disorders.

Register for Details

For more details on financing and valuation for Talaris Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

What is Talaris Therapeutics's ticker symbol?


What is Talaris Therapeutics's stock price?

1.78 as of 3/27/23

Learn more about Talaris Therapeutics

Forge green plus iconForge green minus icon

What is Talaris Therapeutics funding to date?

Talaris Therapeutics has raised $100MM.
Forge green plus iconForge green minus icon

When was Talaris Therapeutics founded?

Talaris Therapeutics was founded in 1900.